Healthtech Late Stage Investors & VC Firms
847 firms in this list, with a median first check of $1M. 197 of them lead rounds. Generated from verified public data and updated continuously.
Bioscience Equity Partners
DubaiLate Stage
1 person
Dubai Cultiv8
DubaiGrowth–Late Stage
1 person
Frontier Path VC
LondonGrowth–Late Stage
1 person
Haibang Capital
HangzhouPre-Seed–Late Stage
1 person
HealthTrend Capital
BostonSeed–Late Stage
1 person
Hokkaido Venture Capital, Inc.
SapporoPre-Seed–Late Stage
1 person
Lundbeckfonden Ventures
CopenhagenPre-Seed–Late Stage
1 person
MedTech Entrepreneurs (MTE)
GräfelfingSeed–Late Stage
1 person
New Legacy
New YorkLate Stage
1 person
Northwell Holdings
New YorkSeed–Late Stage
1 person
Russian Direct Investment Fund (RDIF)
MoscowGrowth–Late Stage
1 person
Sherpa Healthcare Partners
Grand CaymanSeed–Late Stage
1 person
Teewinot Ventures
Pre-Seed–Late Stage
1 person
The Finger Group
Los AngelesSeed–Late Stage
1 person
TriWise Capital
ShenzhenPre-Seed–Late Stage
1 person
AXIS Participaciones Empresariales
MadridSeed–Late Stage$810K – $43.2M
4 people
Biomark Capital
GreenwichSeries A–Late Stage$5M – $10M
4 people
Solus Capital
BudapestSeed–Late Stage$32.4K – $4.3M
4 people
Prospect Hill Growth Partners
WalthamGrowth–Late Stage
New Leaf Venture Partners
New YorkSeed–Late Stage
5 people
Hellman & Friedman
San FranciscoGrowth–Late Stage
Ziegler Link-age Funds
MilwaukeeSeed–Late Stage
Boxer Capital, LLC
San DiegoSeed–Late Stage
Bracket Capital
Los AngelesSeed–Late Stage
Related lists
Healthtech Investors & VC Firms (3208)Late Stage Investors & VC Firms (2864)Healthtech Seed Investors & VC Firms (2488)Healthtech Series A Investors & VC Firms (2210)Healthtech Investors & VC Firms in United States (1616)Healthtech Pre-Seed Investors & VC Firms (1328)Healthtech Series B Investors & VC Firms (1216)Healthtech Growth Investors & VC Firms (1213)Late Stage Investors & VC Firms in United States (1101)Late Stage Investors & VC Firms in Global (857)
Data sourced from public filings and firms' own websites — see our methodology.









